Allergan and Heptares Announce Alzheimer’s Disease Treatment R&D and Commercialization Partnership

Allergan and Heptares Announce Alzheimer’s Disease Treatment R&D and Commercialization Partnership
AllerganlogoDublin, Ireland-based global pharmaceutical company Allergan and Heptares Therapeutics, a clinical-stage pharmaceutical company whose proprietary technologies have created new medicines with the potential to transform Heptares logoAlzheimer's disease, have entered into a global research and development and commercialization partnership for the treatment of Alzheimer's disease (AD) and other neurological disorders. With the partnership, Allergan will license exclusive global rights to the pipeline of novel subtype-selective muscarinic receptor agonists that Heptares has under development for Alzheimer's and other major disorders. Heptares is a wholly-owned subsidiary of Japanese multinational Sosei Group. Its proprietary StaR technology and structure-based drug design (SBDD) capabilities have enabled creation of new medicines targeting G protein-coupled receptors (GPCRs) -- a "superfamily" of receptors linked to a wide range of human diseases. The ability of Heptares to engineer and develop medicines that address highly validated, yet historically undruggable, GPCRs has attract
Subscribe or to access all post and page content.

Leave a Comment

Your email address will not be published. Required fields are marked *